225Ac-PSMA-617 Augmentation After Insufficient Response Under 177Lu-PSMA-617 Radioligand Therapy in mCRPC: Evaluation of Outcome and Safety From a Prospective Registry (REALITY Study)
225 Ac-PSMA-617 augmented 177 Lu-PSMA-617 radioligand therapy seems to be an effective escalating treatment option in patients after failure of conventional 177 Lu-PSMA-617 RLT and represents a promising approach balancing antitumor effect and tolerable side effects.
Authors
- Caroline Burgard (ORCID: https://orcid.org/0000-0003-1522-8860)
- Arne Blickle (ORCID: https://orcid.org/0009-0009-2460-7249)
- Fadi Khreish (ORCID: https://orcid.org/0000-0002-1036-7477)
- Samer Ezziddin (ORCID: https://orcid.org/0000-0003-4110-3375)
- Sven Petto
- Lea Sophie Nagel
- Mark Bartholomä (ORCID: https://orcid.org/0000-0002-0361-2833)
- Stephan Maus (ORCID: https://orcid.org/0000-0002-5131-526X)
- Moritz B. Bastian
- Andrea Schaefer-Schuler (ORCID: https://orcid.org/0000-0002-2439-5786)
- Florian Rosar (ORCID: https://orcid.org/0000-0002-2985-4099)
- Tilman Speicher
Institutions
- Fulda University of Applied Sciences (DE)
- Saarland University (DE)
Publication Details
- Journal
- Clinical Nuclear Medicine
- Published
- 2024-12-31
- DOI
- https://doi.org/10.1097/rlu.0000000000005640
- Citations
- 6
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 2.51